ViraCor Laboratories launches new cytomegalovirus test

ViraCor Laboratories, a provider of molecular diagnostic testing for infectious diseases, has launched a new cytomegalovirus antiviral resistance test that reportedly provides diagnosis days faster than other tests on the market.

Developed in ViraCor’s laboratories, the molecular test accurately detects key genetic mutations associated with antiviral resistance in cytomegalovirus (CMV) in three days or less. Turnaround time on most CMV antiviral resistance tests is up to two weeks.

By quickly and accurately identifying if a patient has an antiviral resistant CMV infection, physicians can begin or modify the appropriate treatment regiments faster, which reduces healthcare costs and potentially saves lives, the company said.

As part of this new testing service, ViraCor provides scientific analysis and clinical interpretation of gene mutations associated with antiviral resistance.

Steve Kleiboeker, chief scientific officer of ViraCor, said: In patients with compromised immune systems, it is critical for doctors to start the right CMV treatment quickly – before serious infection sets in. When we created our CMV antiviral resistance testing service at ViraCor, we were committed to providing the fastest turnaround time possible.

We start processing every sample the day we receive it so that doctors can detect antiviral resistant strains of CMV in their patients within a few days, start the right treatment and avoid complications from infection.